Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy...
Our project focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which we have already shown an unprecedented association with the clinical outcome of patients in various...
Our project focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which we have already shown an unprecedented association with the clinical outcome of patients in various inflammatory diseases, for a therapeutic use in inflammatory bowel diseases (IBD). IBD is a disabling chronic inflammatory process that affects young individuals and causes many life-altering symptoms, and represents a risk factor for colon cancer. Existing treatments are complex, with most people requiring lifelong medications as well as dietary and lifestyle modifications, and some requiring surgery. In this context, the development of new therapeutic approaches appears essential and immunotherapy and cell-based therapy are particularly promising strategies for this disease.
Teams from Nantes have a strong expertise in the field of human immunology, mucosal immunology and immunotherapeutic strategies applied to various pathological conditions, including gut inflammatory diseases. They recently identified a novel microbiota-induced Treg subset, associated with good prognosis in IBD patients, thus representing a promising candidate for innovative immunotherapeutic approaches.
Based on the limitation to develop immunotherapy approach for human diseases by using animal models due to immune system specificities/differences and ethical considerations, we opted for the development of an ex vivo human preclinical model that will reconstitute the physiological complexity of the human gut. Teams from Strasbourg have a strong experience and already set-up models of organoids in different pathological systems, that will perfectly fit to be used as ex vivo preclinical models for this project.
This proposal aims thus at providing a pre-clinical package including i) the proof of concept that a cellular immunotherapy using the identified Tregs subset represents a treatment for IBDs and ii) the reglementary pre-clinical in vitro and in vivo toxicity.ver más
02-11-2024:
Generación Fotovolt...
Se ha cerrado la línea de ayuda pública: Subvenciones destinadas al fomento de la generación fotovoltaica en espacios antropizados en Canarias, 2024
01-11-2024:
ENESA
En las últimas 48 horas el Organismo ENESA ha otorgado 6 concesiones
01-11-2024:
FEGA
En las últimas 48 horas el Organismo FEGA ha otorgado 1667 concesiones
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.